论文部分内容阅读
目的评价盐酸拓扑替康(金喜素Topotecan)联合顺铂治疗小细胞肺癌(SCLC)的疗效和不良反应。方法金喜素1.2mg/(m2·d)静脉滴注,第1～5天;顺铂20～30mg/(m2·d),静脉滴注,第1～3天,21天为1个周期,2～3个周期后判定疗效及不良反应。结果SCLC患者25例,完全缓解4例,部分缓解12例,稳定6例,进展3例,总有效率为64%。主要不良反应为骨髓抑制和胃肠道症状。结论金喜素联合顺铂疗效较好,不良反应可耐受,可作为SCLC一线或二线用药。
Objective To evaluate the efficacy and adverse reactions of Topotecan Hydrochloride combined with cisplatin in the treatment of small cell lung cancer (SCLC). Methods Goldsmeat 1.2mg / (m2 · d) intravenous drip, the first to fifth days; cisplatin 20 ~ 30mg / (m2 · d), intravenous drip, the 1st to 3rd days, 21 days for a cycle, 2 ~ 3 cycles to determine the efficacy and adverse reactions. Results Twenty-five patients with SCLC had complete remission in 4 cases, partial remission in 12 cases, stable in 6 cases and progression in 3 cases. The total effective rate was 64%. The main adverse reactions were myelosuppression and gastrointestinal symptoms. Conclusion The combination of cilium and cisplatin is effective and the adverse reactions are tolerable. It can be used as a first-line or second-line SCLC.